SRC and cancer: However, treatment with Src inhibitors such as Dasatinib increases the infection rate in patients with cancer, and this was suggested to occur because Dasatinib affects the immune system by reduction of neutrophil adhesion and recruitment into injured tissue (Parsons & Parsons, 2004; Zarbock, 2012).